Commercial
Uncorking the compliance bottlenecks in digital
The sudden demand for digital content this year has created serious compliance bottlenecks that pharma is racing to overcome with new processes and technology
More Commercial Articles
Commercial
Creating a holistic customer experience
Finding solutions to unmet customer needs means harnessing the combined power of medical and marketing skills – and creating a culture to match
Commercial
Adapting to the multichannel imperative: A special report
Pharma’s gradual evolution into digital-first commercial has become urgent in the COVID-19 world. A comprehensive multi-channel approach including the use of digital tools to enhance customer engagement will transform pharma sales.
Commercial
Australia’s field force: evolving on fast forward
Australian pharma’s field force roles are changing fast and the new digital-first environment is driving a need for new approaches and new skillsets
Access and Evidence
Survey results: Accelerating digital transformation during COVID-19
View the results of a survey of over 1000 pharma executives on the impact COVID-19 has had and will have on their operations
Commercial
Customer centricity in a changed world
Pharma’s marketeers are having to rapidly change their approach to customers, field force roles and digital in the midst of the pandemic
Multichannel
Virtual Trade Show Best Practices: Intelligent Medical Objects and HiMSS
A new way of thinking and acting is needed for virtual marketing in the post COVID-19 world, says Paul Schrimpf of management consultant Prophet
Multichannel
Towards the sales force of the near future
Blending the digital and the personal can transform engagement, focus sales activity and help meet HCPs’ fast evolving needs if done right
Commercial
The changing nature of pharma sales: A conversation on many levels
The new approach to sales marries state of the art analytics with a classical approach to engagement
Commercial
Time to embrace social media
Patients are turning to social media as never before and pharma needs to catch up